Winning Strategies For Oral Dosage Form Development And Manufacturing

In a recent article, Dave Miller, CSO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Failure to identify a compound’s red flags—bioavailability, stability, processability, etc.—early in development often manifests as program delays or failures. These setbacks can be avoided through complete molecular characterization, which can de-risk development and accelerate entry into human studies while also increasing the probability of clinical success. AustinPx’s origin is based around KinetiSol, which is becoming the world’s premier technology for amorphous solid dispersions (ASDs), an increasingly important element of bioavailability enhancement (BAE).